☆ 4.6 Article

Retrospective Analysis of the Correlation of MSI-h/dMMR Status and Response to Therapy for Endometrial Cancer: RAME Study, a Multicenter Experience

CANCERS (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Medicine, General & Internal

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer

Ramez N. Eskander et al.

Summary: This study collected data from 816 patients with endometrial cancer and found that adding pembrolizumab to standard chemotherapy significantly prolonged progression-free survival in advanced or recurrent endometrial cancer patients compared to chemotherapy alone.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Medicine, General & Internal

Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

M. R. Mirza et al.

Summary: Dostarlimab plus carboplatin-paclitaxel significantly improved progression-free survival in patients with endometrial cancer, particularly in the mismatch repair-deficient microsatellite instability-high population.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Oncology

Cancer statistics, 2022

Rebecca L. Siegel et al.

Summary: Each year, the American Cancer Society compiles data on cancer occurrence and outcomes in the United States. The latest data shows that breast and prostate cancer progress has stagnated, while lung cancer has shown improvements in survival rates. Lung cancer incidence for advanced disease has declined while localized-stage rates have increased, resulting in higher survival rates. Mortality patterns align with incidence trends, with lung cancer deaths declining rapidly, breast cancer deaths slowing, and prostate cancer deaths stabilizing.

CA-A CANCER JOURNAL FOR CLINICIANS (2022)

添加到收藏夹

Article Oncology

Pembrolizumab in Patients With Microsatellite Instability-High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study

David M. O'Malley et al.

Summary: Pembrolizumab demonstrated durable antitumor activity and encouraging survival outcomes in previously treated patients with MSI-H/dMMR endometrial cancer.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer

V Makker et al.

Summary: Lenvatinib plus pembrolizumab significantly prolongs progression-free survival and overall survival compared to chemotherapy in advanced endometrial cancer patients.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Oncology

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study

Ana Oaknin et al.

Summary: Dostarlimab demonstrated durable antitumor activity in patients with endometrial cancer, with a manageable safety profile.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

添加到收藏夹

Review Oncology

Endometrial cancer in Lynch syndrome

Shuangshuang Zhao et al.

Summary: Lynch syndrome (LS) is caused by germline pathogenic variants in mismatch repair (MMR) genes, leading to LS-associated endometrial cancer (LS-EC) which has specific clinicopathologic features. Screening, diagnosis, surveillance, prevention and treatment for LS-EC have significantly advanced, with recommendations for universal LS screening among EC patients.

INTERNATIONAL JOURNAL OF CANCER (2022)

添加到收藏夹

Article Oncology

Non-classical phenotypes of mismatch repair deficiency and microsatellite instability in primary and metastatic tumors at different sites in Lynch syndrome

Zhiyu Li et al.

Summary: The non-classical phenotypes of mismatch repair deficiency (dMMR) and microsatellite instability (MSI) are observed in patients with Lynch syndrome.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Adjuvant therapy for endometrial cancer in the era of molecular classification: radiotherapy, chemoradiation and novel targets for therapy

Anne Sophie V. M. van den Heerik et al.

Summary: Endometrial cancer is primarily treated with surgery, with adjuvant treatments such as radiotherapy and chemotherapy being considered based on clinico-pathological risk factors. Recent studies have shown the effectiveness of different treatment strategies for different risk levels of endometrial cancer, highlighting the importance of personalized treatment approaches. Molecular classification and targeted treatments are emerging as potential advancements in the field, with ongoing trials exploring their impact on patient outcomes.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2021)

添加到收藏夹

Review Medicine, General & Internal

Endometrial cancer

Vicky Makker et al.

Summary: This comprehensive review provides updates on the epidemiology, pathophysiology, diagnosis, treatment, and patient quality-of-life considerations in the management of endometrial cancer. The Primer by Makker and colleagues summarizes the epidemiology, pathophysiology, diagnosis, treatment, and future research directions for endometrial cancer.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹

Review Obstetrics & Gynecology

Molecular Classification and Emerging Targeted Therapy in Endometrial Cancer

Ting-Tai Yen et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2020)

添加到收藏夹

Article Oncology

Adjuvant treatment improves overall survival in women with high-intermediate risk early-stage endometrial cancer with lymphovascular space invasion

Ji Son et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2020)

添加到收藏夹

Article Oncology

Molecular Classification of the PORTEC-3 Trial for High-Risk Endometrial Cancer: Impact on Prognosis and Benefit From Adjuvant Therapy

Alicia Leon-Castillo et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Article Oncology

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

David S. Miller et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

添加到收藏夹

Review Oncology

Endometrial Cancer: An Overview of Pathophysiology, Management, and Care

Kelly Passarello et al.

SEMINARS IN ONCOLOGY NURSING (2019)

添加到收藏夹

Article Oncology

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Stephanie M. de Boer et al.

LANCET ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Clinical consequences of upfront pathology review in the randomised PORTEC-3 trial for high-risk endometrial cancer

S. M. de Boer et al.

ANNALS OF ONCOLOGY (2018)

添加到收藏夹

Article Oncology

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer

Tara E. Soumerai et al.

CLINICAL CANCER RESEARCH (2018)

添加到收藏夹

Article Oncology

A clinically applicable molecular-based classification for endometrial cancers

A. Talhouk et al.

BRITISH JOURNAL OF CANCER (2015)

添加到收藏夹

Article Pathology

Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative

Ellen Stelloo et al.

MODERN PATHOLOGY (2015)

添加到收藏夹

Article Oncology

Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1

Brooke E. Howitt et al.

JAMA ONCOLOGY (2015)

添加到收藏夹

Article Oncology

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Lola Rahib et al.

CANCER RESEARCH (2014)

添加到收藏夹

Article Oncology

Endometrial Cancer and Lynch Syndrome: Clinical and Pathologic Considerations

Larissa A. Meyer et al.

CANCER CONTROL (2009)

添加到收藏夹

Article Oncology

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer

D. Pectasides et al.

GYNECOLOGIC ONCOLOGY (2008)

添加到收藏夹

Article Oncology

Microsatellite instability and epigenetic inactivation of MLH1 and outcome of patients with endometrial carcinomas of the endometrioid type

Israel Zighelboim et al.

JOURNAL OF CLINICAL ONCOLOGY (2007)

添加到收藏夹

Article Oncology

Paclitaxel and carboplatin in the treatment of advanced or recurrent endometrial cancer: a large retrospective study

M. A. Sovak et al.

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2007)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.